le 5 octobre/October 2023

	The common shares of Mydecine Innovations Inc. have been approved for listing on the CSE.

	Listing and disclosure documents will be available at&nbsp;<a href="https://issuers.thecse.com/en/listings/diversified-industries/mydecine-innovations-group-inc">www.thecse.com</a>&nbsp;on the trading date.

	Mydecine Innovations Group Inc. is a biopharmaceutical company founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

	__________________________

	Les actions ordinaires de Mydecine Innovations Inc. ont été approuvées pour leur inscription au CSE.

	Les documents de cotation et d'information seront disponibles sur <a href="https://issuers.thecse.com/fr/inscriptions/societes-diversifiees/mydecine-innovations-group-inc">www.thecse.com</a> à la date de négociation.

	Mydecine Innovations Group Inc. est une société biopharmaceutique fondée pour accroître l'accès des médecins aux médicaments modulateurs de la sérotonine. Des recherches récentes ont démontré le potentiel thérapeutique des substances psychédéliques telles que la psilocybine et la MDMA pour traiter des maladies incurables telles que la douleur, l'anxiété, la dépression, la dépendance et le SSPT, ainsi que les troubles neurodégénératifs. Mydecine pense que ces composés peuvent être plus sûrs, plus efficaces et plus accessibles aux patients et aux professionnels de la santé grâce à la chimie médicamenteuse moderne associée à l'intelligence artificielle (IA). Mydecine développe des médicaments innovants pour des indications cibles présentant des taux de mortalité élevés, qui manquent d'innovation depuis des décennies et sont contrôlées par des sociétés dominantes.
<table border="1" cellpadding="1" cellspacing="1" >
<tbody>
<tr>
<td >
				Issuer/Émetteur:</td>
<td >
				Mydecine Innovations Group Inc.</td>
</tr>
<tr>
<td >
				Security Type/Titre:</td>
<td >
				Common&nbsp;Shares/Actions&nbsp;ordinaires</td>
</tr>
<tr>
<td >
				Symbol(s)/Symbole(s):</td>
<td >
				MYCO</td>
</tr>
<tr>
<td >
				Number of securities issued and outstanding/&nbsp;Titres&nbsp;émis&nbsp;et en circulation:</td>
<td >
				45 207 458</td>
</tr>
<tr>
<td >
				Number of Securities reserved for issuance/&nbsp;Titres&nbsp;réservés&nbsp;pour&nbsp;émission:</td>
<td >
				22 608 492</td>
</tr>
<tr>
<td >
				CSE Sector/Catégorie:</td>
<td >

					Diversified Industries/Sociétés diversifiées
</td>
</tr>
<tr>
<td >
				CUSIP:</td>
<td >
				62849F 20 0</td>
</tr>
<tr>
<td >
				ISIN:</td>
<td >
				CA 62849F 20 0 8</td>
</tr>
<tr>
<td >
				Boardlot/Quotité:</td>
<td >
				500</td>
</tr>
<tr>
<td >
				Trading&nbsp;Currency/Monnaie&nbsp;de&nbsp;négociation:</td>
<td >
				CDN$/$CDN</td>
</tr>
<tr>
<td >
				Listing Date/Date de l’inscription:</td>
<td >
				le&nbsp;6 OCT&nbsp;2023</td>
</tr>
<tr>
<td >
				Other Exchanges/Autres&nbsp;marches:</td>
<td >
				N/A</td>
</tr>
<tr>
<td >
				Fiscal Year&nbsp;end /Clôture&nbsp;de&nbsp;l'exercice&nbsp;financier:</td>
<td >
				le 31&nbsp;décembre/December</td>
</tr>
<tr>
<td >
				Transfer Agent/Agent des&nbsp;transferts:</td>
<td >
				National Securities Administrators Ltd.</td>
</tr>
</tbody>
</table>

	The Exchange is accepting Market Maker applications for MYCO. Please email:&nbsp;<a href="mailto:Trading@theCSE.com">Trading@theCSE.com</a>

	If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>

	Pour&nbsp;toute&nbsp;question, pour&nbsp;obtenir&nbsp;de&nbsp;l’information&nbsp;supplémentaire&nbsp;veuillez&nbsp;communiquer&nbsp;avec&nbsp;le service des inscriptions au 416 367-7340 ou par&nbsp;courriel&nbsp;à&nbsp;l’adresse:&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>

Mydecine Innovations Group Inc. 

2023-1009 - New Listing - Mydecine Innovations Group Inc. (MYCO)

CSE25™

CSE Composite Index®

In this series, we delve deep into the experiences of CSE listed companies, exploring their past successes and future opportunities.

CSE Issuer Spotlight

**Follow us** for the **latest news** from the CSE

 The CSE provides a modern and efficient alternative for companies looking to access the Canadian public capital markets.

The Canadian Securities Exchange (CSE)

Learn how we streamline issuer regulation through enhanced disclosure, practical and effective regulatory oversight, and modern technology.

Listing on the CSE

Learn more about the companies we list and how to get started trading on the CSE.

Investing in Listed Companies

Learn how we lower costs, reduce complexity, and provide market making opportunities for the dealer community.

Trading on the CSE

Whether you’re an investor, business leader, or simply looking to learn more, start your journey with the CSE here.

Get Started

From announcements and market updates to in-depth interviews with company leaders - stay informed with the latest from the CSE.

Latest from the CSE

Discover newly listed companies on the CSE through our series of bite-sized interviews with company leaders.

Get to know our latest listings

Listed Company News

Market Activity

List with the CSE

Find a home for your next big idea.

Frequently Asked Questions

How does being listed on the CSE affect me as a shareholder?

Where do I get information and trade CSE listed securities?

Where can I find an RSS feed for listed company news?

Where is the CSE recognized?

Upcoming Events

join the list

Join our mailing list to receive buy-in notifications

The CSE provides a superior exchange experience by investing in our customers’ success with innovation, dedication, and passion.

Where innovation, passion, and trust intersect

We strive to be the most innovative exchange in Canada. We aim to offer unlimited global access and a customized client-centric experience while delivering the lowest cost of public capital. 

We are Canada's entrepreneurial exchange

The most searched CSE listed companies on thecse.com

Recent Quotes

Get the latest regulatory announcements from the CSE concerning its Listings Policies, Trading Rules and functionality and other important industry developments.

Notices

Get the latest information about new CSE listings, the appointment of Market Makers, market events, and other news.

Bulletins

Stay informed with CSE listed company news, providing transparency and accountability to shareholders and the public.

Company News

Stay Informed

The **total volume** traded on the CSE today is

Connect with our professionals and listing experts at industry events and conferences.